RxDoctor Payments Data

Rafael Perez Rodriguez, MD

Epilepsy · Eau Claire, WINPI 1750732863

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 53 payments — averaging $31.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$355
  • Pfizer$299
  • UCB, Inc.$150
  • Avanir Pharmaceuticals, Inc.$144
  • Novartis$134
  • Sunovion Pharmaceuticals Inc.$112
  • plus $463 from 9 others

What the payments were for

  • Food & beverage$1,64199%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few epilepsy providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$58,701
Medicare patients
317
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe58$48,439
EpidiolexCannabidiol (Cbd)14$43,546
GlatopaGlatiramer Acetate13$34,944
Nurtec OdtRimegepant Sulfate22$30,548
FycompaPerampanel12$14,418
XcopriCenobamate13$14,151
QuliptaAtogepant12$12,883
Emgality PenGalcanezumab-Gnlm13$10,873
Lacosamide103$8,662
Levetiracetam312$8,574
Divalproex Sodium ErDivalproex Sodium70$6,140
Lamotrigine141$4,239
Oxcarbazepine46$3,591
Carbamazepine ErCarbamazepine33$3,458
Divalproex Sodium54$3,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$299$30,54822 claims
Eisai Inc.Fycompa$58$14,41812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other epilepsy in Eau Claire

Where these figures come from

Is this you, or does something look wrong? →